Current Science

Open Access Open Access  Restricted Access Subscription Access

Radiation and radioisotopes for human healthcare applications


Affiliations
1 Advanced Centre for Treatment Research & Education in Cancer, Kharghar, Tata Memorial Centre, Navi Mumbai 410 210, India; Homi Bhabha National Institute, DAE, Anushaktinagar, Mumbai 400 094, India
2 Radiation Medicine Centre, BARC, Parel, Mumbai 400 012, India; Homi Bhabha National Institute, DAE, Anushaktinagar, Mumbai 400 094, India
3 Tata Memorial Hospital, Parel, Mumbai 400 012, India; Homi Bhabha National Institute, DAE, Anushaktinagar, Mumbai 400 094, India
4 Tata Memorial Centre, Parel, Mumbai 400 012, India; Homi Bhabha National Institute, DAE, Anushaktinagar, Mumbai 400 094, India
 

The use of radiation and radioisotopes in human healthcare has been one of the early developments in the non-power applications of nuclear science. The field encompasses different facets of the use of radiation in the diagnosis and therapy of a wide variety of diseases, particularly cancer, the formidable challenge of the present century. There has been a significant advan­cement in different areas such as diagnostic radiology, diagnostic nuclear medicine, therapeutic radiation and therapeutic nuclear medicine, including theranostic applications in personalized medicine. The R&D efforts of the Department of Atomic Energy towards ensuring indigenous availability of established radiopharmaceuticals and treatment modalities as well as to develop emerging ones for state-of-the-art radiation-related services have been significant over the years. This article presents the current status, recent developments, clinical translation of developed products and prospects related to the use of radioisotopes and radiation in the two premiere research institutions of DAE, viz. BARC and TMC.
User
Notifications
Font Size

  • Hricak, H. et al., Managing radiation use in medical imaging: a multifaceted challenge. Radiology, 2011, 258, 889–905.

  • Kumar, M., Shanavas, M., Sidappa, A. and Kiran, M., Cone beam computed tomography – know its secrets. J. Int. Oral Health, 2015, 7, 64–68.

  • Lorente-Ramos, R., Azpeitia-Armán, J., Muñoz-Hernández, A., García-Gómez, J. M., Díez-Martínez, P. and Grande-Bárez, M., Dual-energy X-ray absorptiometry in the diagnosis of osteoporosis: a practical guide. Am. J. Roentgenol., 2011, 196, 897–904.

  • Joe, B. N. and Sickles, E. A., The evolution of breast imaging: past to present. Radiology, 2014, 273, S23–S44.

  • Liguori, C. et al., Emerging clinical applications of computed tomography. Med. Devices (Auckl.), 2015, 8, 265–278; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467659/.

  • Okamoto, K., Ito, J., Sakao, K. and Yoshimura, S., The principle of digital subtraction angiography and radiological protection. Interv. Neuroradiol., 2000, 6, 25–31.

  • Blahd, W. H., Ben Cassen and the development of the rectilinear scanner. Semin. Nucl. Med., 1996, 26, 165–170.

  • Stefanović, L., The beginnings and development of diagnostic imaging in nuclear medicine. Med. Pregl., 2001, 54, 289–296.

  • Eckelman, W. C., Radiolabeling with technetium-99m to study high-capacity and low-capacity biochemical systems. Eur. J. Nucl. Med., 1995, 22, 249–263.

  • Wrenn, F. R., Good, M. L. and Handler, P., The use of positron-emitting radioisotopes for the localization of brain tumors. Science, 1951, 113, 525–527.

  • Phelps, M. E., Hoffman, E. J., Mullani, N. A. and Ter-Pogossian, M. M., Application of annihilation coincidence detection to transaxial reconstruction tomography. J. Nucl. Med., 1975, 16, 210–224.

  • Kuhl, D. E., Edwards, R. Q., Ricci, A. R., Yacob, R. J., Mich, T. J. and Alavi, A., The Mark IV system for radionuclide computed tomography of the brain. Radiology, 1976, 121, 405–413.

  • Kallini, J. R., Gabr, A., Salem, R. and Lewandowski, R. J., Transarterial radioembolization with yttrium-90 for the treatment of hepatocellular carcinoma. Adv. Ther., 2016, 33, 699–714.

  • Thakral, P., Sen, I., Das, S. S., Manda, D., Virupakshappa, C. B. and Malik, D., Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease. Br. J. Radiol., 2021, 94, 20210403.

  • Ebbers, S. C., Braat, A. J. A. T., Moelker, A., Stokkel, M. P. M., Lam, M. G. E. H. and Barentsz, M. W., Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial). Trials, 2020, 21, 141.

  • Al-Sarraf, M. et al., Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J. Clin. Oncol., 1998, 16, 1310–1317.

  • Nigro, N. D., Seydel, H. G., Considine, B., Vaitkevicius, V. K., Leichman, L. and Kinzie, J. J., Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer, 1983, 51, 1826–1829.

  • Gupta, S. et al., Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J. Clin. Oncol., 2018, 36, 1548–1555.

  • Wolf, G. T. et al., Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N. Engl. J. Med., 1991, 324, 1685–1690.

  • James, N. D. et al., Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N. Engl. J. Med., 2012, 366, 1477–1488.

  • Palma, D. A. et al., Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet, 2019, 393, 2051–2058.

  • Pillai, M. R. A., Chakraborty, S., Das, T., Venkatesh, M. and Ramamoorthy, N., Production logistics of 177Lu for radionuclide therapy. Appl. Radiat. Isot., 2003, 59, 109–118.

  • Banerjee, S., Pillai, M. R. A. and Knapp, F. F., Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem. Rev., 2015, 115, 2934–2974.

  • Das, T. and Banerjee, S., Theranostic applications of lutetieum-177 in radionuclide therapy. Curr. Radiopharm., 2016, 9, 94–101.

  • Mitra, A. et al., On the separation of yttrium-90 from high-level liquid waste: purification to clinical-grade radiochemical precursor, clinical translation in formulation of 90Y-DOTATATE patient dose. Cancer Biother. Radiopharm., 2021, 36, 143–159.

  • Avram, A. M., Zukotynski, K., Nadel, H. R. and Giovanella, L., Management of differentiated thyroid cancer: the standard of care. J. Nucl. Med., 2022, 63, 189–195.

  • Pryma, D. A. et al., Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J. Nucl. Med., 2019, 60, 623–630.

  • Ahmadzadehfar, H., Rahbar, K., Essler, M. and Biersack, H. J., PSMA-based theranostics: a step-by-step practical approach to diagnosis and therapy for mCRPC patients. Semin. Nucl. Med., 2020, 50, 98–109.

  • Basu, S. et al., One decade of ‘bench-to-bedside’ peptide receptor radionuclide therapy with indigenous [177Lu]Lu-DOTATATE obtained through ‘direct’ neutron activation route: lessons learnt including practice evolution in an Indian setting. Am. J. Nucl. Med. Mol. Imag., 2020, 10, 178–211.

  • Suman, S. et al., Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort. Br. J. Radiol., 2019, 92, 20190380.

  • The Electromagnetic Spectrum: Non-Ionizing Radiation; https://www.cdc.gov/nceh/radiation/nonionizing_radiation.html (last accessed on 10 July 2022).

  • Hall, E. J. and Giaccia, A. J., Textbook of Radiobiology, 2019, 8th edn.

  • Hamada, N. and Fujimichi, Y., Classification of radiation effects for dose limitation purposes: history, current situation and future prospects. J. Radiat. Res., 2014, 55(4), 629–640; doi:10.1093/jrr/rru019.Epub 2014 May 3. PMID: 24794798; PMCID: PMC4100010.

  • Leenhouts, H. P. and Chadwick, K. H., The molecular basis of stochastic and nonstochastic effects. Health Phys., 1989, 57, 343–348.

  • Morton, L. M., Onel, K., Curtis, R. E., Hungate, E. A. and Armstrong, G. T., The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults. Am. Soc. Clin. Oncol. Educ. Book, 2014, e57–e67; doi:10.14694/EdBook_AM.2014.34.e57.

  • Dracham, C. B., Shankar, A. and Madan, R., Radiation induced secondary malignancies: a review article. Radiat. Oncol. J., 2018, 36, 85–94.

  • Berrington de Gonzalez, A. et al., Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship. Int. J. Radiat. Oncol. Biol. Phys., 2013, 86, 224–233.


Abstract Views: 338

PDF Views: 117




  • Radiation and radioisotopes for human healthcare applications

Abstract Views: 338  |  PDF Views: 117

Authors

Sharmila Banerjee
Advanced Centre for Treatment Research & Education in Cancer, Kharghar, Tata Memorial Centre, Navi Mumbai 410 210, India; Homi Bhabha National Institute, DAE, Anushaktinagar, Mumbai 400 094, India
Sandip Basu
Radiation Medicine Centre, BARC, Parel, Mumbai 400 012, India; Homi Bhabha National Institute, DAE, Anushaktinagar, Mumbai 400 094, India
Akshay D. Baheti
Tata Memorial Hospital, Parel, Mumbai 400 012, India; Homi Bhabha National Institute, DAE, Anushaktinagar, Mumbai 400 094, India
Suyash Kulkarni
Tata Memorial Hospital, Parel, Mumbai 400 012, India; Homi Bhabha National Institute, DAE, Anushaktinagar, Mumbai 400 094, India
Venkatesh Rangarajan
Tata Memorial Hospital, Parel, Mumbai 400 012, India; Homi Bhabha National Institute, DAE, Anushaktinagar, Mumbai 400 094, India
Prashant Nayak
Tata Memorial Hospital, Parel, Mumbai 400 012, India; Homi Bhabha National Institute, DAE, Anushaktinagar, Mumbai 400 094, India
Vedang Murthy
Tata Memorial Hospital, Parel, Mumbai 400 012, India; Homi Bhabha National Institute, DAE, Anushaktinagar, Mumbai 400 094, India
Anuj Kumar
Tata Memorial Hospital, Parel, Mumbai 400 012, India; Homi Bhabha National Institute, DAE, Anushaktinagar, Mumbai 400 094, India
Sarbani G. Laskar
Tata Memorial Hospital, Parel, Mumbai 400 012, India; Homi Bhabha National Institute, DAE, Anushaktinagar, Mumbai 400 094, India
J. P. Agarwal
Tata Memorial Hospital, Parel, Mumbai 400 012, India; Homi Bhabha National Institute, DAE, Anushaktinagar, Mumbai 400 094, India
Sudeep Gupta
Advanced Centre for Treatment Research & Education in Cancer, Kharghar, Tata Memorial Centre, Navi Mumbai 410 210, India; Homi Bhabha National Institute, DAE, Anushaktinagar, Mumbai 400 094, India
R. A. Badwe
Tata Memorial Centre, Parel, Mumbai 400 012, India; Homi Bhabha National Institute, DAE, Anushaktinagar, Mumbai 400 094, India

Abstract


The use of radiation and radioisotopes in human healthcare has been one of the early developments in the non-power applications of nuclear science. The field encompasses different facets of the use of radiation in the diagnosis and therapy of a wide variety of diseases, particularly cancer, the formidable challenge of the present century. There has been a significant advan­cement in different areas such as diagnostic radiology, diagnostic nuclear medicine, therapeutic radiation and therapeutic nuclear medicine, including theranostic applications in personalized medicine. The R&D efforts of the Department of Atomic Energy towards ensuring indigenous availability of established radiopharmaceuticals and treatment modalities as well as to develop emerging ones for state-of-the-art radiation-related services have been significant over the years. This article presents the current status, recent developments, clinical translation of developed products and prospects related to the use of radioisotopes and radiation in the two premiere research institutions of DAE, viz. BARC and TMC.

References





DOI: https://doi.org/10.18520/cs%2Fv123%2Fi3%2F388-395